Sort   by:  
 Page size 
UnknownHyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Not available
S-EPMC8499695 | biostudies-literature
UnknownA fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Not available
S-EPMC10410135 | biostudies-literature
UnknownSix-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays.
Not available
S-EPMC7803622 | biostudies-literature
UnknownClinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study.
Not available
S-EPMC8298657 | biostudies-literature
UnknownMeasurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
Not available
S-EPMC12770953 | biostudies-literature
UnknownClassification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
Not available
S-EPMC8546044 | biostudies-literature
UnknownIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Not available
S-EPMC4134521 | biostudies-literature
Sort   by:  
 Page size